一个用于制造一次性系统的生物安全工具箱。

Q3 Medicine
Richard Denk, Reinhold Maeck, Dirk Motzkus, Carola Dreier, Bernhard Steidle, Andreas Seiffert, Stefan Woog, Harald Eriksson, Charlotte Hieke, Chris Williams, Susanne Konrad, Joachim Regel, Sven Verguts
{"title":"一个用于制造一次性系统的生物安全工具箱。","authors":"Richard Denk, Reinhold Maeck, Dirk Motzkus, Carola Dreier, Bernhard Steidle, Andreas Seiffert, Stefan Woog, Harald Eriksson, Charlotte Hieke, Chris Williams, Susanne Konrad, Joachim Regel, Sven Verguts","doi":"10.5731/pdajpst.2025-000003.1","DOIUrl":null,"url":null,"abstract":"<p><p>As markets for recombinant biologicals constantly grow, risks related to the biohazardous materials used are not yet always understood and assessed systematically. Thus, there is a strong need to systematically assess technical solutions in GMP area and best practices for all steps in biotechnological production using biohazardous materials up to biological safety level 2. Especially Viral vectors, Virus based vaccines are more coming to market as novel therapies, asking for different safety requirements.As Single Use Solutions (SUS) are widely used in clinical- and production scale in Upstream and Downstream processing until Final fill operations, new practices must be developed with a different approach enabling production under BSL2.Production of biologics which are produced in BSL2 area regime using SU solutions must be reviewed under different aspects in terms of safety for the product + staff equally and probable contamination of the environment. SU Solutions for this new purpose must be differently handled with care from goods entry until final discard of products post usage. The production starting at fabricator of the SUS items itself might require modifications. The design of SUS items for the BSL2 purpose must be tested already in a different way in production, to fulfill the higher safety level regimes to protect the product and operators. In this paper we give examples for considerations how to unpack, store such SUS consumables and which conditions in the facility are favorable in combination with proper staff training Examples of suitable components and existing SUS equipment's for the Upstream- and Downstream processing of such products, to give operators, Suite- and plant managers, A+E with planers and people in regulatory departments the needed information, to enable the safe and regulatory aligned production of such biologic therapies.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A biosafety toolbox for manufacturing with single-use systems.\",\"authors\":\"Richard Denk, Reinhold Maeck, Dirk Motzkus, Carola Dreier, Bernhard Steidle, Andreas Seiffert, Stefan Woog, Harald Eriksson, Charlotte Hieke, Chris Williams, Susanne Konrad, Joachim Regel, Sven Verguts\",\"doi\":\"10.5731/pdajpst.2025-000003.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>As markets for recombinant biologicals constantly grow, risks related to the biohazardous materials used are not yet always understood and assessed systematically. Thus, there is a strong need to systematically assess technical solutions in GMP area and best practices for all steps in biotechnological production using biohazardous materials up to biological safety level 2. Especially Viral vectors, Virus based vaccines are more coming to market as novel therapies, asking for different safety requirements.As Single Use Solutions (SUS) are widely used in clinical- and production scale in Upstream and Downstream processing until Final fill operations, new practices must be developed with a different approach enabling production under BSL2.Production of biologics which are produced in BSL2 area regime using SU solutions must be reviewed under different aspects in terms of safety for the product + staff equally and probable contamination of the environment. SU Solutions for this new purpose must be differently handled with care from goods entry until final discard of products post usage. The production starting at fabricator of the SUS items itself might require modifications. The design of SUS items for the BSL2 purpose must be tested already in a different way in production, to fulfill the higher safety level regimes to protect the product and operators. In this paper we give examples for considerations how to unpack, store such SUS consumables and which conditions in the facility are favorable in combination with proper staff training Examples of suitable components and existing SUS equipment's for the Upstream- and Downstream processing of such products, to give operators, Suite- and plant managers, A+E with planers and people in regulatory departments the needed information, to enable the safe and regulatory aligned production of such biologic therapies.</p>\",\"PeriodicalId\":19986,\"journal\":{\"name\":\"PDA Journal of Pharmaceutical Science and Technology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PDA Journal of Pharmaceutical Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5731/pdajpst.2025-000003.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2025-000003.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

随着重组生物制品市场的不断增长,与所使用的生物有害材料相关的风险尚未得到系统的了解和评估。因此,迫切需要系统地评估GMP领域的技术解决方案和生物技术生产中使用生物危险材料的所有步骤的最佳做法,直至生物安全级别2。特别是病毒载体,病毒疫苗更多地作为新疗法进入市场,要求不同的安全要求。由于一次性解决方案(SUS)广泛用于临床和生产规模的上游和下游加工,直到最终填充操作,因此必须开发新的实践,采用不同的方法实现BSL2下的生产。在BSL2区域使用SU解决方案生产的生物制剂必须从不同方面进行审查,包括对产品和员工的安全性以及对环境的可能污染。用于此新目的的SU解决方案必须以不同的方式处理,从货物进入到产品使用后的最终丢弃。从SUS项目的制造商开始的生产本身可能需要修改。用于BSL2目的的SUS项目的设计必须已经在生产中以不同的方式进行测试,以满足更高的安全级别制度,以保护产品和操作员。在本文中,我们举例说明如何打开包装,储存这些SUS消耗品,以及设施中的有利条件,并结合适当的员工培训,为这些产品的上游和下游加工提供合适的组件和现有SUS设备的例子,为操作员,套件和工厂经理,A+E与刨床和监管部门的人员提供所需的信息。使这类生物疗法的生产安全和符合监管要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A biosafety toolbox for manufacturing with single-use systems.

As markets for recombinant biologicals constantly grow, risks related to the biohazardous materials used are not yet always understood and assessed systematically. Thus, there is a strong need to systematically assess technical solutions in GMP area and best practices for all steps in biotechnological production using biohazardous materials up to biological safety level 2. Especially Viral vectors, Virus based vaccines are more coming to market as novel therapies, asking for different safety requirements.As Single Use Solutions (SUS) are widely used in clinical- and production scale in Upstream and Downstream processing until Final fill operations, new practices must be developed with a different approach enabling production under BSL2.Production of biologics which are produced in BSL2 area regime using SU solutions must be reviewed under different aspects in terms of safety for the product + staff equally and probable contamination of the environment. SU Solutions for this new purpose must be differently handled with care from goods entry until final discard of products post usage. The production starting at fabricator of the SUS items itself might require modifications. The design of SUS items for the BSL2 purpose must be tested already in a different way in production, to fulfill the higher safety level regimes to protect the product and operators. In this paper we give examples for considerations how to unpack, store such SUS consumables and which conditions in the facility are favorable in combination with proper staff training Examples of suitable components and existing SUS equipment's for the Upstream- and Downstream processing of such products, to give operators, Suite- and plant managers, A+E with planers and people in regulatory departments the needed information, to enable the safe and regulatory aligned production of such biologic therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信